top
Please input keywords
Order
*Country
United States
China
France
Germany
Netherlands
United Kingdom
Japan
South Korea
Israel
Australia
Hong Kong, China
New Zealand
Russia
Singapore
Taiwan, China
India
Aland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua & Barbuda
Argentina
Armenia
Aruba
Ascension Island
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bosnia & Herzegovina
Botswana
Brazil
British Indian Ocean Territory
British Virgin Islands
Brunei
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Canary Islands
Cape Verde
Caribbean Netherlands
Cayman Islands
Central African Republic
Ceuta & Melilla
Chad
Chile
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo - Brazzaville
Congo - Kinshasa
Cook Islands
Costa Rica
Côte d’Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czechia
Denmark
Diego Garcia
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands
Faroe Islands
Fiji
Finland
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Honduras
Hungary
Iceland
Indonesia
Iran
Iraq
Ireland
Isle of Man
Italy
Jamaica
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Kosovo
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macau, China
Macedonia
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia
Moldova
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar (Burma)
Namibia
Nauru
Nepal
New Caledonia
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
North Korea
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territories
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn Islands
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Rwanda
Samoa
San Marino
São Tomé & Príncipe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Sint Maarten
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia & South Sandwich Islands
South Sudan
Spain
Sri Lanka
St. Barthélemy
St. Helena
St. Kitts & Nevis
St. Lucia
St. Martin
St. Pierre & Miquelon
St. Vincent & Grenadines
Sudan
Suriname
Svalbard & Jan Mayen
Swaziland
Sweden
Switzerland
Syria
Tajikistan
Tanzania
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad & Tobago
Tristan da Cunha
Tunisia
Turkey
Turkmenistan
Turks & Caicos Islands
Tuvalu
U.S. Outlying Islands
U.S. Virgin Islands
Uganda
Ukraine
United Arab Emirates
United Nations
Uruguay
Uzbekistan
Vanuatu
Vatican City
Venezuela
Vietnam
Wallis & Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
*Province
*City
*Name
*Telephone
*Company
*Position
*Email
*Verification code
*Verification Code
B-hFcRn mice
Strain Name
C57BL/6-Fcgrttm1(FCGRT)Bcgen/Bcgen
Common Name  B-hFcRn mice
Background C57BL/6 Catalog number  110001
Related Genes 
FCGRT(Fc fragment of IgG receptor and transporter)
NCBI Gene ID
14132

mRNA expression analysis


from clipboard


Strain specific analysis of FCGRT gene expression in WT and B-hFcRn mice by RT-PCR.
 Mouse Fcgrt mRNA was detectable in kidney of wild-type (+/+). Human FCGRT mRNA was detectable only in H/H but not in +/+ mice. 


Protein expression analysis


Strain specific analysis of FcRn expression in C57BL/6(+/+) and B-hFcRn mice by western blot.

Kidney was collected from C57BL/6(+/+)  mice  and homozygous B-hFcRn(H/H)  mice and analyzed by western blot with species-specific anti-FcRn antibody. Mouse FcRn was detectable in C57BL/6(+/+) mice. Human FcRn was detectable only in B-hFcRn(H/H)  but not in C57BL/6(+/+) mice.


Serum half-life of Ab1 in B-hFcRn mice



PK profiles in B-hFcRn and C57BL/6 mice IV-dosed at 10 mg/kg with Ab1. Data points from mice with high immune response to the injected antibody, demonstrated by mouse antihuman antibody titers of greater than 1 to 1000 and corresponding to abrupt  PK changes, were excluded in the analyses.


Different type of IgGs pharmacokinetics in B-hFcRn mice


PK profiles in B-hFcRn and C57BL/6 mice IV-dosed at 10 mg/kg with Ab1(IgG1), Ab2(IgG2) and Ab3(IgG3). Data points from mice with high immune response to the injected antibody, demonstrated by mouse antihuman antibody titers of greater than 1 to 1000 and corresponding to abrupt  PK changes, were excluded in the analyses.


The YTE mutation prolongs Abs half-life in B-hFcRn mice


from clipboard


The serum pharmacokinetics profiles for Ab1 and Ab1-YTE are shown. The effect of YTE in prolonging the half-life of antibodies is only observed in B-hFcRn mice but not in wild-type mice.

Serum half-life of commercial antibody drug in B-hFcRn mice 

from clipboard


  •  The test drugs are commercial drugs
  •  The half-life in humans and monkeys of test drugs from research articles
  •  Blood collection: Continuous
  •  Abrupt  PK changes were excluded in the analyses 
  •  Curve fitting: The last three blood collection points
  •  Data are shown in mean ± SEM

Correlation of half-lives of Abs between human, monkey, B-hFcRn and WT mice

from clipboard